Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Alviggi, C, Conforti, A, Esteves, SC, Andersen, CY, Bosch, E, Bühler, K, Ferraretti, AP, De Placido, G, Mollo, A, Fischer, R & Humaidan, P 2018, 'Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review' Fertility and Sterility, vol. 109, no. 4, pp. 644-664. https://doi.org/10.1016/j.fertnstert.2018.01.003

APA

CBE

Alviggi C, Conforti A, Esteves SC, Andersen CY, Bosch E, Bühler K, Ferraretti AP, De Placido G, Mollo A, Fischer R, Humaidan P. 2018. Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review. Fertility and Sterility. 109(4):644-664. https://doi.org/10.1016/j.fertnstert.2018.01.003

MLA

Vancouver

Author

Alviggi, Carlo ; Conforti, Alessandro ; Esteves, Sandro C ; Andersen, Claus Yding ; Bosch, Ernesto ; Bühler, Klaus ; Ferraretti, Anna Pia ; De Placido, Giuseppe ; Mollo, Antonio ; Fischer, Robert ; Humaidan, Peter. / Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review. In: Fertility and Sterility. 2018 ; Vol. 109, No. 4. pp. 644-664.

Bibtex

@article{11024f88f60e4372a9bdab70b2a0c898,
title = "Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review",
abstract = "OBJECTIVE: To assess the role of recombinant human LH (r-hLH) supplementation in ovarian stimulation for ART in specific subgroups of patients.DESIGN: Systematic review.SETTING: Centers for reproductive care.PATIENT(S): Six populations were investigated: 1) women with a hyporesponse to recombinant human FSH (r-hFSH) monotherapy; 2) women at an advanced reproductive age; 3) women cotreated with the use of a GnRH antagonist; 4) women with profoundly suppressed LH levels after the administration of GnRH agonists; 5) normoresponder women to prevent ovarian hyperstimulation syndrome; and 6) women with a {"}poor response{"} to ovarian stimulation, including those who met the European Society for Human Reproduction and Embryology Bologna criteria.INTERVENTION(S): Systematic review.MAIN OUTCOME MEASURE(S): Implantation rate, number of oocytes retrieved, live birth rate, ongoing pregnancy rate, fertilization rate, and number of metaphase II oocytes.RESULT(S): Recombinant hLH supplementation appears to be beneficial in two subgroups of patients: 1) women with adequate prestimulation ovarian reserve parameters and an unexpected hyporesponse to r-hFSH monotherapy; and 2) women 36-39 years of age. Indeed, there is no evidence that r-hLH is beneficial in young (<35 y) normoresponders cotreated with the use of a GnRH antagonist. The use of r-hLH supplementation in women with suppressed endogenous LH levels caused by GnRH analogues and in poor responders remains controversial, whereas the use of r-hLH supplementation to prevent the development of ovarian hyperstimulation syndrome warrants further investigation.CONCLUSION(S): Recombinant hLH can be proposed for hyporesponders and women 36-39 years of age.",
author = "Carlo Alviggi and Alessandro Conforti and Esteves, {Sandro C} and Andersen, {Claus Yding} and Ernesto Bosch and Klaus B{\"u}hler and Ferraretti, {Anna Pia} and {De Placido}, Giuseppe and Antonio Mollo and Robert Fischer and Peter Humaidan",
note = "Copyright {\circledC} 2018 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.fertnstert.2018.01.003",
language = "English",
volume = "109",
pages = "644--664",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc",
number = "4",

}

RIS

TY - JOUR

T1 - Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review

AU - Alviggi, Carlo

AU - Conforti, Alessandro

AU - Esteves, Sandro C

AU - Andersen, Claus Yding

AU - Bosch, Ernesto

AU - Bühler, Klaus

AU - Ferraretti, Anna Pia

AU - De Placido, Giuseppe

AU - Mollo, Antonio

AU - Fischer, Robert

AU - Humaidan, Peter

N1 - Copyright © 2018 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - OBJECTIVE: To assess the role of recombinant human LH (r-hLH) supplementation in ovarian stimulation for ART in specific subgroups of patients.DESIGN: Systematic review.SETTING: Centers for reproductive care.PATIENT(S): Six populations were investigated: 1) women with a hyporesponse to recombinant human FSH (r-hFSH) monotherapy; 2) women at an advanced reproductive age; 3) women cotreated with the use of a GnRH antagonist; 4) women with profoundly suppressed LH levels after the administration of GnRH agonists; 5) normoresponder women to prevent ovarian hyperstimulation syndrome; and 6) women with a "poor response" to ovarian stimulation, including those who met the European Society for Human Reproduction and Embryology Bologna criteria.INTERVENTION(S): Systematic review.MAIN OUTCOME MEASURE(S): Implantation rate, number of oocytes retrieved, live birth rate, ongoing pregnancy rate, fertilization rate, and number of metaphase II oocytes.RESULT(S): Recombinant hLH supplementation appears to be beneficial in two subgroups of patients: 1) women with adequate prestimulation ovarian reserve parameters and an unexpected hyporesponse to r-hFSH monotherapy; and 2) women 36-39 years of age. Indeed, there is no evidence that r-hLH is beneficial in young (<35 y) normoresponders cotreated with the use of a GnRH antagonist. The use of r-hLH supplementation in women with suppressed endogenous LH levels caused by GnRH analogues and in poor responders remains controversial, whereas the use of r-hLH supplementation to prevent the development of ovarian hyperstimulation syndrome warrants further investigation.CONCLUSION(S): Recombinant hLH can be proposed for hyporesponders and women 36-39 years of age.

AB - OBJECTIVE: To assess the role of recombinant human LH (r-hLH) supplementation in ovarian stimulation for ART in specific subgroups of patients.DESIGN: Systematic review.SETTING: Centers for reproductive care.PATIENT(S): Six populations were investigated: 1) women with a hyporesponse to recombinant human FSH (r-hFSH) monotherapy; 2) women at an advanced reproductive age; 3) women cotreated with the use of a GnRH antagonist; 4) women with profoundly suppressed LH levels after the administration of GnRH agonists; 5) normoresponder women to prevent ovarian hyperstimulation syndrome; and 6) women with a "poor response" to ovarian stimulation, including those who met the European Society for Human Reproduction and Embryology Bologna criteria.INTERVENTION(S): Systematic review.MAIN OUTCOME MEASURE(S): Implantation rate, number of oocytes retrieved, live birth rate, ongoing pregnancy rate, fertilization rate, and number of metaphase II oocytes.RESULT(S): Recombinant hLH supplementation appears to be beneficial in two subgroups of patients: 1) women with adequate prestimulation ovarian reserve parameters and an unexpected hyporesponse to r-hFSH monotherapy; and 2) women 36-39 years of age. Indeed, there is no evidence that r-hLH is beneficial in young (<35 y) normoresponders cotreated with the use of a GnRH antagonist. The use of r-hLH supplementation in women with suppressed endogenous LH levels caused by GnRH analogues and in poor responders remains controversial, whereas the use of r-hLH supplementation to prevent the development of ovarian hyperstimulation syndrome warrants further investigation.CONCLUSION(S): Recombinant hLH can be proposed for hyporesponders and women 36-39 years of age.

U2 - 10.1016/j.fertnstert.2018.01.003

DO - 10.1016/j.fertnstert.2018.01.003

M3 - Journal article

VL - 109

SP - 644

EP - 664

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 4

ER -

ID: 54949738